Senseonics (SENS) said Tuesday the US Food and Drug Administration has cleared the Eversense 365 continuous glucose monitoring, or CGM, system for people with Type 1 and Type 2 diabetes aged 18 years and older.
Eversense 365 provides one year of use, the company said.
Senseonics said it plans to launch Eversense 365 in the US in early Q4.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.